New Delhi, Oct 25:  

Drug firm Lupin today said it has received the final approval from the US health regulator for its testosterone topical solution.

The company has received final approval for its testosterone topical solution, 30 mg per actuation from the United States Food and Drug Administration (USFDA) to market the product, Lupin said in a BSE filing.

The approved product is a generic version of Eli Lilly and Company’s Axiron topical solution, it added.

According to IMS MAT June 2017 data, testosterone topical solution had sales of $244.2 million in the US, Lupin said.

The testosterone topical solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, it added.

Shares of Lupin were trading at Rs 1,028.50, up 0.19 per cent from the previous close on BSE.

(This article was published on October 25, 2017)
Post Comment

Get more of your favourite news delivered to your inbox

Please enter your email. Thank You.
Newsletter has been successfully subscribed.